AGM
LCTX icon

Alpine Global Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Alpine Global Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,477
Closed -$13.1K – 266
2025
Q2 		$13.1K Buy
+14,477
New +$8.59K ﹤0.01% 151

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's LCTX Position: Q3 2025 in Review

Alpine Global Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 14,477 shares — an estimated $13.1K sold.

Alpine Global Management first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $13.1K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Alpine Global Management reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alpine Global Management sold 14,477 Lineage Cell Therapeutics shares in Q3 2025, an estimated $13.1K.
  • Alpine Global Management first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
  • Alpine Global Management's Lineage Cell Therapeutics position peaked at $13.1K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Alpine Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.